MUC1 mucin as a target for immunotherapy of cancer: Muc1 based immunotherapeutic strategies

摘要: It has been more than a 100 years since the first attempts of cancer immunotherapy were made based on assumption that tumor cells are recognized as foreign by immune system. Over last decade, there considerable increase in our understanding responses against and antigenic structures Tumor antigens have classified into distinct categories: tissue-specific differentiation antigens, tumor-specific unique shared antigens. MUC1 belongs to both category.. Although is expressed normal tissue well tumors, it extensively studied antigen basic science applied research for number exciting reasons. Some these include its interesting protein structure, extensive glycosylation (which altered tumors) increased expression tumors changes cellular distribution upon malignant transformation. In addition, very variety human ductal adenocarcinomas. All facts justify use candidate immunotherapy. The object this chapter highlight current past data concerning experimental clinical using target tumor-rejection antigen.